CIPLA LIMITED group: subsidiaries and structure
Public Limited Company (Ltd) · MUMBAI, India · LEI 335800KMJJYEDDK82Q34
10subsidiaries
3countries
8held directly
1lapsed LEIs
3links on accounts older than 24 months
0ISINs of subsidiaries
Summary
CIPLA LIMITED is the ultimate parent of 10 subsidiaries with LEIs in 3 countries, as reported to GLEIF. 8 are held directly; the others sit below intermediate companies. The largest numbers are in India (8), in the United Kingdom (1) and in the United States (1). 1 of the subsidiaries has a lapsed LEI, and 3 links rest on accounts older than 24 months. GLEIF's ISIN mapping lists 2 ISINs for the parent and 0 ISINs for its subsidiaries.
Written from GLEIF data using fixed, reviewed sentence templates.
Subsidiaries by country
Data-quality notes (AssetCensus analysis)
No group-level data-quality notes in this data release.
3 subsidiaries have data-quality notes; they are listed on each company page.
Group structure
Indentation shows the direct parent reported to GLEIF.
Subsidiaries
| Company | Country | City | LEI | Accounts year | Notes |
|---|---|---|---|---|---|
| CIPLA (EU) LIMITED | United Kingdom | Addlestone | 549300MMI7M2RE8EGD31 | 2025 | |
| CIPLA HEALTH LIMITED | India | MUMBAI | 335800EF1UKQE25U5930 | 2025 | |
| CIPLA PHARMA AND LIFE SCIENCES LIMITED | India | MUMBAI | 3358001Y1AJDOWP1QB25 | 2025 | |
| CIPLA PHARMACEUTICALS LIMITED | India | MUMBAI | 335800H17JGFR4CI7G31 | 2025 | |
| GOLDENCROSS PHARMA LIMITED | India | MUMBAI | 335800FZPXFBC1JOSI39 | 2024 | > 24 months |
| JAY PRECISION PHARMACEUTICALS PRIVATE LIMITED | India | MUMBAI | 335800NB8KVI4IXDUP33 | 2025 | |
| MEDISPRAY LABORATORIES PRIVATE LIMITED | India | KUNDAIM | 335800EIIXYBDM65HX19 | 2025 | |
| MEDITAB SPECIALITIES LIMITED | India | MUMBAI | 33580024IOVCZFQ5NR86 | 2025 | |
| SITEC LABS LIMITED | India | NAVI MUMBAI | 335800841DBDRFYJ1H47 | 2024 | > 24 months |
| INVAGEN PHARMACEUTICALS INC. | United States | ALBANY | 549300PSQTOK7P8ZE722 | 2018 | lapsed > 24 months |